- Posted April 6, 2014 by
Dr. Lorrin Pang FDA insights
While attending a GMO Rally in Kahului, Maui on March 30, 2014 I spoke to Dr. Lorrin Pang and questioned him about issues within the FDA science community. I was delighted to learn about this once confidential internal FDA study highlighted below. Although not the best news one could hope for it definitely shed light on the severity of the issue at hand.
Dr. Lorrin Pang explains some of the issues facing FDA scientists in regards to GMO safety.
The specific online PDF document can be downloaded and reviewed by the public.
FDA Science and Mission at Risk.
Report of the Subcommittee on Science and Technology
Prepared For FDA Science Board
URL shortened: http://1.usa.gov/1mKEJat
The FDA scientists point out:
“The FDA cannot fulfill its mission because its scientific base has eroded and its scientific organizational structure is weak”.
“The FDA cannot fulfill its mission because its scientific workforce does not have sufficient capacity and capability”.
“The FDA cannot fulfill its mission because its information technology (IT) infrastructure is inadequate”.
“Finding: FDA does not have the capacity to ensure the safety of food for the nation”.
“Finding: The development of medical products based on “new science” cannot be adequately regulated by the FDA”.
“Finding: There is insufficient capacity in modeling, risk assessment and analysis”.
“Finding: The FDA science agenda lacks a coherent structure and vision, as well as effective coordination and prioritization”.
“Finding: The FDA has substantial recruitment and retention challenges”.
“Finding: The FDA has an inadequate and ineffective program for scientist performance”.
“Finding: The FDA has inadequate funding for professional development”.
“Finding: The FDA has not taken sufficient advantage of external and internal collaborations”.
“Finding: The Subcommittee believes that there is evidence of important, but slow, progress to improve information sciences and technology at the FDA over the past few years, yet significant gaps remain”.
“Finding: The FDA lacks the information science capability and information infrastructure to fulfill its regulatory mandate”.
“Finding: The FDA cannot provide the information infrastructure support to regulate products based on new science”.
“Finding: The FDA IT infrastructure is obsolete, unstable, and lacks sufficient controls to ensure continuity of operations or to provide effective disaster recovery services”.
“Finding: The IT workforce is insufficient and sub optimally organized”.
“Finding: The FDA has experienced decreasing resources in the face of increasing responsibilities”.
“Finding: Recommendations of excellent FDA reviews are seldom followed”.